WHO ICTRP trial
Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by…
EUCTR2008-001430-27-AT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-001430-27-AT |
|---|---|
| Public title | Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluation of safety and efficacy - RevliRit |
| Scientific title | Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluation of safety and efficacy - RevliRit |
| Primary sponsor | Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Austria |
| Conditions | Untreated chronic lymphocytic leukaemia (B-CLL) MedDRA version: 9.1 Level: LLT Classification code 10003946 Term: B-Lymphocytic, CLL (Kiel Classification) |
| Interventions | Trade Name: Revlimid Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lenalidomide Other descriptive name: 3-(4´aminoisoindoline-l´-one)-1-piperidine-2,6-dione Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Jul 23, 2008 |
| Secondary IDs | CLL-5 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: